4.12

2.49% 0.10

After Hours: 4.12

Ironwood Pharmaceuticals Inc (IRWD)

Overview News Price History Option Chain Financials Discussions Forecast

Ironwood Pharmaceuticals Inc stock is traded at $4.12, with a volume of 2.70M. It is up +2.49% in the last 24 hours and down -18.58% over the past month. Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Previous Close:

$4.02

Open:

$4.02

24h Volume:

2.70M

Relative Volume:

1.38

Market Cap:

$644.55M

Revenue:

$400.57M

Net Income/Loss:

$9.21M

P/E Ratio:

-0.6821

EPS:

-6.04

Net Cash Flow:

$146.36M

1W Performance:

+0.98%

1M Performance:

-18.58%

6M Performance:

-52.70%

1Y Performance:

-57.22%

1-Day Range:

$3.875

$4.135

1-Week Range:

$3.8633

$4.18

52-Week Range:

$3.79

$15.70

Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile

Name

Ironwood Pharmaceuticals Inc

Sector

Healthcare (1190)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

617-621-7722

Address

100 SUMMER STREET, SUITE 2300, BOSTON, MA

Employee

267

Twitter

@ironwoodpharma

Next Earnings Date

2024-08-08

Latest SEC Filings

IRWD's Discussions on Twitter

Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-17-24	Initiated	Craig Hallum	Buy
Dec-14-23	Initiated	Wells Fargo	Overweight
Nov-09-23	Initiated	Jefferies	Buy
Sep-28-23	Initiated	JMP Securities	Mkt Outperform
Sep-02-22	Initiated	CapitalOne	Overweight
Apr-22-22	Initiated	Piper Sandler	Overweight
Sep-30-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-17-20	Initiated	Northland Capital	Outperform
Jul-10-19	Resumed	Credit Suisse	Neutral
Mar-27-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-25-19	Upgrade	H.C. Wainwright	Sell → Neutral
Jan-24-19	Upgrade	JP Morgan	Underweight → Neutral
Nov-07-18	Downgrade	Credit Suisse	Outperform → Neutral
Nov-07-18	Downgrade	JP Morgan	Neutral → Underweight
Jul-23-18	Initiated	H.C. Wainwright	Sell
May-09-18	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jan-05-18	Downgrade	BofA/Merrill	Buy → Underperform
Dec-06-17	Downgrade	Mizuho	Buy → Neutral
Jul-21-17	Downgrade	JP Morgan	Overweight → Neutral
May-03-17	Initiated	Wells Fargo	Outperform
Apr-07-17	Reiterated	Mizuho	Buy
Feb-22-17	Reiterated	Barclays	Equal Weight
Nov-04-16	Reiterated	Mizuho	Buy
Oct-24-16	Reiterated	Wedbush	Neutral
Oct-10-16	Reiterated	Mizuho	Buy
Sep-27-16	Reiterated	WallachBeth	Hold

View All

Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News

12:58 PM

Analyzing Ratios: Ironwood Pharmaceuticals Inc (IRWD)’s Financial Story Unveiled - The Dwinnex

12:58 PM

11:28 AM

How does Ironwood Pharmaceuticals Inc (IRWD) change from a tortoise to a hare? - SETE News

11:28 AM

01:39 AM

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Bought by Dark Forest Capital Management LP - Defense World

01:39 AM

Sep 27, 2024

A company insider recently sold 9,910 shares of Ironwood Pharmaceuticals Inc [IRWD]. Should You Sale? - Knox Daily

Sep 27, 2024

Sep 26, 2024

Profund Advisors LLC Sells 86,472 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World

Sep 26, 2024

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Purchased by Armistice Capital LLC - MarketBeat

Sep 26, 2024

Sep 25, 2024

A History of Outperforming Analyst Forecasts and Beating the Odds: Ironwood Pharmaceuticals Inc (IRWD) - SETE News

Sep 25, 2024

Sep 24, 2024